20:57 , Aug 5, 2019 |  BC Extra  |  Company News

Takeda latest to partner with Sosei Heptares in GPCR discovery deal

In its second deal in the past month, Sosei partnered with Takeda to discover, develop and commercialize small molecules and biologics against multiple undisclosed G protein-coupled receptor targets. Sosei Group Corp. (Tokyo:4565) is eligible to...
23:31 , Jul 16, 2019 |  BC Extra  |  Company News

Genentech adds three discovery partnerships to build out pipeline

Through a trio of deals with Convelo, Skyhawk and Sosei Heptares announced Tuesday, Genentech is adding programs that could refresh its early stage neurology pipeline, as well as its oncology and other early R&D. Global...
22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
00:12 , May 31, 2019 |  BC Innovations  |  Translation in Brief

New target for Oncoceutics' GPCR-targeting compounds

Two academic teams have discovered Oncoceutics’ GPCR-targeting products kill cancer via an alternative mechanism: triggering apoptosis by activating a mitochondrial protease. Oncoceutics Inc. is developing a pipeline of imipridones to antagonize or agonize GPCRs including...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
17:33 , Jan 9, 2019 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure; ischemia/reperfusion injury Cell culture and mouse studies suggest inhibiting GRK2 localization to the mitochondria could help treat heart failure following cardiac ischemia/reperfusion injury. In a mouse model of heart failure following ischemia/reperfusion...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
22:58 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
17:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Cell culture and mouse studies suggest inhibiting GRK2 could help treat influenza A infection. In a human alveolar basal epithelium cell line infected with human or avian strains of influenza A, an...